Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2023-11-23T16:37:07Z | - |
dc.date.available | 2023-11-23T16:37:07Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 1678-8140 | * |
dc.identifier.other | OAK-33934 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/266549 | - |
dc.description.abstract | Background and Purpose: In recent years, the treatment landscape for breast cancer has undergone significant advancements, with the introduction of several new anticancer agents. One such agent is trastuzumab emtansine (T-DM1), an antibody drug conjugate that has shown improved outcomes in both early and advanced breast cancer. However, there is currently a lack of comprehensive evidence regarding the safety profile of combining T-DM1 with radiation therapy (RT). In this study, we aim to provide a summary of the available data on the safety of combining RT with T-DM1 in both early and metastatic breast cancer settings. Materials and Methods: This systematic review and meta-analysis project is part of the consensus recommendations by the European Society for Radiotherapy and Oncology (ESTRO) Guidelines Committee on integrating RT with targeted treatments for breast cancer. A thorough literature search was conducted using the PUBMED/MedLine, Embase, and Cochrane databases to identify original studies focusing on the safety profile of combining T-DM1 with RT. Results: After applying eligibility criteria, nine articles were included in the meta-analysis. Pooled data from these studies revealed a high incidence of grade 3 + radionecrosis (17%), while the rates of grade 3 + radiation-related pneumonitis (<1%) and skin toxicity (1%) were found to be very low. Conclusion: Although there is some concern regarding a slight increase in pneumonitis when combining T-DM1 with postoperative RT, the safety profile of this combination was deemed acceptable for locoregional treatment in non-metastatic breast cancer. However, caution is advised when irradiating intracranial sites concurrently with T-DM1. There is a pressing need for international consensus guidelines regarding the safety considerations of combining T-DM1 and RT for breast cancer. © 2023 The Author(s) | * |
dc.language | English | * |
dc.publisher | Elsevier Ireland Ltd | * |
dc.subject | Breast cancer | * |
dc.subject | Meta-analysis | * |
dc.subject | Radiotherapy | * |
dc.subject | Systematic review | * |
dc.subject | T-DM1 | * |
dc.subject | Trastuzumab emtansine | * |
dc.title | Safety profile of trastuzumab-emtansine (T-DM1) with concurrent radiation therapy: A systematic review and meta-analysis | * |
dc.type | Review | * |
dc.relation.volume | 186 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Radiotherapy and Oncology | * |
dc.identifier.doi | 10.1016/j.radonc.2023.109805 | * |
dc.identifier.wosid | WOS:001049777100001 | * |
dc.identifier.scopusid | 2-s2.0-85166661686 | * |
dc.author.google | Salvestrini V. | * |
dc.author.google | Kim K. | * |
dc.author.google | Caini S. | * |
dc.author.google | Alkner S. | * |
dc.author.google | Ekholm M. | * |
dc.author.google | Skyttä T. | * |
dc.author.google | Becherini C. | * |
dc.author.google | Coles C.E. | * |
dc.author.google | Kaidar-Person O. | * |
dc.author.google | Offersen B. | * |
dc.author.google | de Azambuja E. | * |
dc.author.google | Visani L. | * |
dc.author.google | Cortes J. | * |
dc.author.google | Harbeck N. | * |
dc.author.google | Rugo H.S. | * |
dc.author.google | Isacke C.M. | * |
dc.author.google | Marangoni E. | * |
dc.author.google | Morandi A. | * |
dc.author.google | Lambertini M. | * |
dc.author.google | Poortmans P. | * |
dc.author.google | Livi L. | * |
dc.author.google | Meattini I. | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240222162403 | * |